Post Profile

Bristol's drug cocktail cuts kidney cancer death risk 37 percent

MADRID (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday.
read more


Related Posts

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Health : Reuters: Health

(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges...

Ono warns on profit after government halves price of cancer drug Opdivo

Health : Reuters: Health

TOKYO (Reuters) - Ono Pharmaceutical Co cut its annual profit outlook by a quarter on Wednesday, hit by the Japanese government's decision to halve the price of cancer drug Opdivo that it co-developed with Bristol Myers Squibb Co.

No silver lining in failed Bristol cancer drug trial

Health : Reuters: Health

COPENHAGEN (Reuters) - Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closel...

Japan sets 50 percent price cut for Bristol Myers' Opdivo cancer drug

Health : Reuters: Health

(Reuters) - Japan's health ministry has set a 50 percent cut in the price of Opdivo, a costly immune system-boosting cancer drug produced by Bristol Myers Squibb Co and marketed in the country by Ono Pharmaceutical Co Ltd, Ono Pharm...

After melanoma surgery, Bristol's Opdivo offers new care standard

Health : Reuters: Health

MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.


Copyright © 2016 Regator, LLC